Individual Safety Report

3309023-7-00-01

MEDWATCH

THE FDA MEDICAL PRODUCTS REPORTING PROGRAM

M. RES. INST. USA
use by user-facilities,
rs and manufacturers for
MANDATORY reporting

Page 1 of 3

Approved by FDA on 09/25/95

Mfr report # PRIUSA1999002535

UF/Dist report #

FDA Use Only

A. Patient information

1. Patient identifier	2. Age at time of event: or Date of birth:	3. Sex	4. Weight
?-? In confidence	53 yr ??/???/??	☒ female ☐ male	UNK lbs or UNK kgs

B. Adverse event or product problem

1. ☒ Adverse event and/or ☐ Product problem (e.g., defects/malfunctions)

2. Outcomes attributed to adverse event (check all that apply)
- ☒ death 05/05/98 (mo/day/yr)
- ☐ life-threatening
- ☒ hospitalization - initial or prolonged
- ☐ disability
- ☐ congenital anomaly
- ☐ required intervention to prevent permanent impairment/damage
- ☐ other:

3. Date of event (mo/day/yr): 05/03/98

4. Date of this report (mo/day/yr): 07/16/99

5. Describe event or problem

Report published in 1998 Annual Report of Poison Control Centers Toxic Exposure Surveillance System (case 264) of a 53-year-old (sex unspecified) who died following ingestion of acetaminophen with codeine and warfarin (doses, date unspecified) for an unknown reason. Blood concentration acetaminophen 369 mcg/mL. Chronicity was unknown for acetaminophen with codeine.

Additional information received 08-Jul-99: A 53-year-old woman described as a "chronic acetaminophen user/abuser" (up to 16 g/day of acetaminophen with codeine) was found unresponsive on 03-May-98. The poison center was called at 14:13 after she had been placed on a ventilator and given a loading dose of N-acetylcysteine. She had a history of depression, drug abuse, arthritis and deep vein thrombosis and was taking venlafaxine hydrochloride, hydroxychloroquine phosphate, enalapril maleate, prednisone, omeprazole and ancovert. It was thought that she overdosed on acetaminophen with codeine and warfarin. The patient was hypotensive in the 70's on (Cont.)

6. Relevant tests/laboratory data, including dates

Blood concentration acetaminophen 369 mcg/mL

Additional information received 08-Jul-99: 03-May-98 on admission blood pressure 70's, blood pressure 110 on dopamine, blood sugar 58, pH 7.11, PO2 133, PCO2 11, AST 279, LDH 737, bilirubin 1.4, INR 19, acetylsalicylic acid 4.3 mg/dL
04-May-98 at 09:45 blood pressure 150/8[illegible], (Cont.)

7. Other relevant history, including preexisting medical conditions (e.g., allergies, race, pregnancy, smoking and alcohol use, hepatic/renal dysfunction, etc.)

Drug abuse (presc. and otc medicine)
Additional information received 08-Jul-99: "chronic acetaminophen user/abuser", depression, arthritis, deep vein thrombosis

RECEIVED
JUL 22 1999
DSS
BY

Submission of a report does not constitute an admission that medical personnel, user facility, distributor, manufacturer or product caused or contributed to the event.

3500A Facsimile

C. Suspect medication(s)

1. Name (give labeled strength & manufacturer, if known)
#1 TYLENOL WITH CODEINE (unspecified) (ACETAMINOPHEN-
#2 WARFARIN (WARFARIN)
(Cont.)

2. Dose, frequency & route used
#1 16 g, daily, oral
#2 oral

3. Therapy dates (if unknown, give duration) from/to (or best estimate)
#1 ??/???/?? - Stopped
#2 ??/???/?? - Stopped

4. Diagnosis for use (indication)
#1 UNKNOWN
#2 UNKNOWN

5. Event abated after use stopped or dose reduced
#1 ☐ yes ☐ no ☒ doesn't apply
#2 ☐ yes ☐ no ☐ doesn't apply

6. Lot # (if known)
#1
#2

7. Exp. date (if known)
#1
#2

8. Event reappeared after reintroduction
#1 ☐ yes ☐ no ☒ doesn't apply
#2 ☐ yes ☐ no ☐ doesn't apply

9. NDC # - for product problems only (if known)

10. Concomitant medical products and therapy dates (exclude treatment of event)
1) EFFEXOR (VENLAFAXINE HYDROCHLORIDE)
2) PLAQUENIL (HYDROXYCHLOROQUINE PHOSPHATE)
3) VASOTEC (ENALAPRIL
(Cont.)

D. All manufacturers

1. Contact office - name/address (& mfring site for devices)
R.W. JOHNSON PHARM. RES. INST. USA
DIV. OF ORTHO PHARMACEUTICAL CORP.
920 U.S. Route 202
P.O. Box 300
Raritan NJ 08869
USA
(Informing Unit)

2. Phone number: 908-704-4504

3. Report source (check all that apply)
- ☐ foreign
- ☐ study
- ☒ literature
- ☐ consumer
- ☒ health professional
- ☐ user facility
- ☐ company representative
- ☐ distributor
- ☐ other:

4. Date received by manufacturer (mo/day/yr): 07/08/99

5. (A) NDA # 85-055
IND #
PLA #
pre-1938 ☐ yes
OTC product ☐ yes

6. If IND, protocol #

Type of report (check all that apply)
- ☐ 5-day ☒ 15-day
- ☐ 10-day ☐ periodic
- ☐ Initial ☒ follow-up # 1

8. Adverse event term(s)
1) THERAPEUTIC RESPONSE INCREASED
2) DRUG ABUSE
3) HYPOTENSION
4) PROTHROMBIN DECREASED
5) HEPATIC ENZYMES
(Cont.)

9. Mfr. report number
PRIUSA1999002535

E. Initial reporter

1. Name, address & phone #
Dr. Toby Litovitz
American Association of Poison Control Centers
3201 New Mexico Ave, Suite 310
Washington, DC 20016
USA
Phone #:202-362-7493

2. Health professional?	3. Occupation	4. Initial reporter also sent report to FDA
☒ yes ☐ no	Physician	☐ yes ☐ no ☒ unk

P.O. Box 300
Raritan NJ 08869
USA

B. Adverse event or product problem

B.5 Describe event or problem (Cont...)

admission and was maintaining a blood pressure of 110 on dopamine. She was admitted to the intensive care unit and activated charcoal was given. At 20:00 she was improving; dopamine was discontinued and she was maintaining fluids. N-acetylcysteine was continued via nasogastric tube. Vitamin K 10 mg was given x 1. Admission labs were the following: blood sugar 58, pH 7.11, PO2 133, PCO2 11, AST 279, LDH 737, bilirubin 1.4, INR 19, acetylsalicylic acid 4.3 mg/dL, acetaminophen 369 mcg/mL. At 03:15 on 04-May-98 the patient remained on a ventilator and a midazolam hydrochloride drip. At 09:45 blood pressure 150/80, heart rate 110, temperature 99 F, AST 1773, ALT 1426, LDH 1719, total bilirubin 0.9, direct bilirubin 0.6, prothrombin time 31.3, partial prothrombin time 42, INR 10.5. The patient had no evidence of bleeding at this time. At 20:50 the patient was stable, but had been placed on dopamine for a while and had a fever of 102 F with blood cultures pending. She had a positive bowel sounds and was passing AC stools. Repeat laboratory tests at 18:00 showed an improvement in liver function tests: AST 1082, ALT 1354, LDH 964, total bilirubin 0.8, direct bilirubin 0.5, INR 10; alkaline phosphatase 180. N-acetylcysteine was continued and another dose of vitamin K was given. A follow-up call at 3:50 on 06-May-98 revealed the patient had expired on 05-May-98.

B.6 Relevant tests/laboratory data, including dates (Cont...)

heart rate 110, temperature 99 F, AST 1773, ALT 1426, LDH 1719, total bilirubin 0.9, direct bilirubin 0.6, prothrombin time 31.3, partial prothrombin time 42, INR 10.5; at 18:00 AST 1082, ALT 1354, LDH 964, total bilirubin 0.8, direct bilirubin 0.5, INR 10; alkaline phosphatase 180; at 20:50 temperature 102 F

C. Suspect medication (Cont...)

Seq No.	: 1
C.1 Suspect medication	: TYLENOL WITH CODEINE(unspecified)(ACETAMINOPHEN/CODEINE)

C10. Concomitant medical products

Seq No.	: 1
Concomitant Medical Product	: EFFEXOR(VENLAFAXINE HYDROCHLORIDE)
Dose, frequency & route used	: 1) unknown
Seq No.	: 2
Concomitant Medical Product	: PLAQUENIL(HYDROXYCHLOROQUINE PHOSPHATE)
Dose, frequency & route used	: 1) unknown
Seq No.	: 3
Concomitant Medical Product	: VASOTEC(ENALAPRIL MALEATE)
Dose, frequency & route used	: 1) unknown
Seq No.	: 4
Concomitant Medical Product	: PREDNISONE(PREDNISONE)
Dose, frequency & route used	: 1) unknown
Seq No.	: 5
Concomitant Medical Product	: PRILOSEC(OMEPRAZOLE)
Dose, frequency & route used	: 1) unknown
Seq No.	: 6
Concomitant Medical Product	: ANTIVERT(ANCOVERT)
Dose, frequency & route used	: 1) unknown

G. All manufacturers

8. Adverse event term(s)

5) HEPATIC ENZYMES INCREASED
6) STUPOR

Source of report (Literature):

Seq No.	: 1
Author	: Toby Litovitz
Year	: 99

Individual Safety Report

3309023-7-00-03

USA

Continuation Sheet for FDA-3500A Form

Mfr. eport # : PRIUSA1999002535

Date of this report : 07/16/99

Article title : 1998 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System